menu
    • menu
    [{"orgOrder":0,"company":"Formation Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"ASN008","moa":"NaV Channel","graph1":"Dermatology","graph2":"Phase II","graph3":"Formation Bio","amount2":0.37,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.37,"dosageForm":"Topical Gel","sponsorNew":"Formation Bio \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Formation Bio \/ Sanofi"},{"orgOrder":0,"company":"Formation Bio","sponsor":"IMIDomics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"RVW101","moa":"CD226","graph1":"Immunology","graph2":"IND Enabling","graph3":"Formation Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Formation Bio \/ Formation Bio","highestDevelopmentStatusID":"5","companyTruncated":"Formation Bio \/ Formation Bio"}]

    Find Clinical Drug Pipeline Developments & Deals by Formation Bio

    Menu

    Formation Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Formation Bio

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            Formation Bio

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RVW101

                            Therapeutic Area : Immunology

                            Study Phase : IND Enabling

                            Recipient : IMIDomics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Formation Bio Licenses First-in-Class Anti-CD226 Autoimmune Program from IMIDomics

                            Details : Under the licensing agreement, Formation Bio holds the worldwide rights of RVW101, which is being evaluated for the treatment of ulcerative colitis.

                            Product Name : RVW101

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            July 29, 2025

                            Lead Product(s) : RVW101

                            Therapeutic Area : Immunology

                            Highest Development Status : IND Enabling

                            Recipient : IMIDomics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Formation Bio

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed

                            Formation Bio

                            U.S.A arrow
                            ACS Fall 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASN008

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : $372.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Formation Bio Raises Series D to Expand Drug Pipeline and AI-Driven Development Platform

                            Details : The fund aims to advance the pipeline, which includes the company lead product ASN008, a sodium channel blocker. Currently, it is being evaluated for the treatment of atopic dermatitis.

                            Product Name : ASN008

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 26, 2024

                            Lead Product(s) : ASN008

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : $372.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth